IgGenix Inc, a pre-clinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, recently presented insights into the potential for IgE antibody re-engineering in shellfish allergy. These data, generated using IgGenix’s novel patented SEQ SIFTER™ single-cell RNA-sequencing discovery platform, were presented on February 26 during the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, which took place in San Antonio, Texas on February 24-27, 2023.
“Individuals with severe forms of allergic disease have evolved potent IgE responses to otherwise innocuous antigens,” said Ben Chih-Pin Chung, Ph.D., Principal Scientist at IgGenix who presented the findings. “The high afﬁnity and human origin of these antibodies make them promising leads for the future development of IgG allergen-speciﬁc therapies with the potential for enhanced efﬁcacy, safety, and onset of action.”
“Shellfish allergies are the most common food allergies in adults and among the most common food allergies in children. Approximately 2% of the U.S. population reports an allergy to shellfish and many of the first reactions occur in adults. Shellfish allergies are usually lifelong and the only definitive treatment today is strict avoidance however almost all causes of anaphylaxis are due to accidental exposure or cross-contamination. These data from IgGenix are an exciting step towards a shellfish treatment to prevent symptoms in allergic individuals,” said Kari C. Nadeau, MD PhD, IgGenix Co-Founder and John Rock Professor of Climate and Population Studies, Chair, Department of Environmental Health, Harvard T.H. Chan School of Public Health.
“At IgGenix, we are developing a novel approach to prevent severe allergic reactions by re-engineering allergen-specific human antibodies. These data are the potential basis for treatments that may block and prevent life-threatening allergic reactions to shellfish and other food and environmental allergens,” said Derek Croote PhD, Co-Founder and Chief Technical Officer of IgGenix.
Source – BusinessWire